Advances in slowing the progress of diabetic nephropathy

Patient Care

Volumn 35, Issue 18, 2001, Pages 28-41

  Saunders, Carol S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0038976324     PISSN: 0031305X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Brenner B. Reduction of Endpoints in Non-insulin-dependent Diabetes Mellitus With Angiotensin II Antagonist Losartan (RENAAL). Paper presented at: Sixteenth Scientific Meeting of the American Society of Hypertension; May 19, 2001; San Francisco, Calif.
2. Lewis EJ. Irbesartan Diabetic Nephropathy Trial (IDNT). Paper presented at: Sixteenth Scientific Meeting of the American Society of Hypertension; May 19, 2001; San Francisco, Calif.
3. Parving HH. Irbesartan in Type 2 Diabetes with MicroAlbuminuria (IRMA 2). Paper presented at: Sixteenth Scientific Meeting of the American Society of Hypertension; May 19, 2001; San Francisco, Calif.
4. American Diabetes Association. Clinical practice recommendations 2001. Diabetes Care. 2001;24(suppl 1):S69-S72.
5. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis. 1999;33:1004-1010.
6. Lemley KV, Blouch K, Abdullah I, Boothroyd DB, Bennett PH, Myers BD, Nelson RG. Glomerular permselectivrty at the onset of nephropathy in type 2 diabetes mellitus. J Am Soc Nephrol. 2000;11:2095-2105.
7. Hebert LA, Wilmer WA, Falkenhain ME, et al. Renoprotection: One or many therapies? Kidney Int 2001;59:1211-1226.
8. American Diabetes Association. Clinical practice recommendations 2001. Diabetes Care. 2001;24(suppl 1):S33-S43.
9. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-661.
10. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute; 1977. NIH publication 98-4080. Available at: http://www.nhlbi.nih.gov/guidelines/hypertension/jncintro.htm. Accessed June 20, 2001.
11. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001;37:1053-1059.
12. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus N Engl J Med. 1999;341:1127-1133.
13. Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis. 2000;35:597-8105.
14. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
15. Vivian EM, Goebig ML. Slowing the progression of renal disease in diabetic patients. Ann Pharmacother 2001;35:452-463.
16. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. A randomized controlled trial. JAMA 2001;285:2719-2728.
17. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
18. Mann JF, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134:629-636.
19. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet 2001;357:1601-1608.